Description: Discover results of the ongoing SOA COVID-19 Group Life Mortality Survey. It will also compare Group Life mortality results to U.S. general population excess mortality trends, and explore some of the non-COVID drivers of excess mortality.

Description: Discuss changes in group life waiver of premium claim recovery and mortality experience since the 2005 table was released, the development of the 2023 table, and the new statutory valuation standard approved by the National Association of Insurance Commissioners (NAIC).

Description: This session will bring together public health care leaders in COVID-10 vaccine delivery from both the U.S. and the UK to discuss and compare operational implications of the COVID-19 vaccine rollout in their countries, and how those programs ultimately affected hospitalization utilization and mortality rates for members of their communities.

Description: With record numbers of job openings, rising interest rates, the highest inflation in decades, and the possibility of a recession, it has been an unusual and challenging time for the U.S. economy. Explore the impact that recent economic trends may have on group disability insurance, including morbidity, growth, and financial performance..

Description: Discover a comparison of U.S. and international mandated leave programs which mandate employers to provide a minimum level of benefits to employees for qualifying leaves of absence, such as parental leave or medical leave.

Description: In late 2021, U.S. Congress passed the Consolidated Appropriations Act (CCA), which requires group health plans and health insurers to submit information regarding the costs of prescription drug costs and other health care services each year to the federal government. Learn how this data can be useful to anyone responsible for forecasting and budgeting.

Description: The SOA’s Individual Disability Experience Committee (IDEC) has reviewed industry experience for both claims incidence and terminations. Based on this review, the committee has published two reports with experience modifiers that when applied to the 2013 IDIVT table best fit experience from 2005 to 2015. During this session, the factors and their development will be reviewed as well as their impact on active and disabled life reserves.

Description: "Direct medical costs for cancer care topped $209 billion nationally in 2020, accounting for a significant proportion of all health care expenditures in the U.S. Indirect costs are also significant, encompassing loss of productivity, wages, leisure time and decreased quality of life. The way cancer programs deliver and are reimbursed for care is rapidly changing. As the cost of cancer care continues to rise, several new value-based care programs - both public and private - have attempted to curb these rising costs. Learn about the current landscape of VBC oncology programs, several key challenges and opportunities with oncology analytics, as well as anticipated evolution of cancer care in the near future. Topics include: Current VBC oncology landscape, including a more detailed discussion on CMS' latest oncology program, Enhancing Oncology Model (EOM) Discussion on current challenges and opportunities with oncology analytics, including some advanced methodologies that have been developed based on documented clinical pathways to better understand cost drivers Future state of oncology care including emerging pharmaceuticals and novel therapies, personalized care regimens, and other clinical innovations"

Description: Telehealth continues to be a story of unrealized potential than realized success. Find out what's pushing telehealth forward as a means of remote healthcare and the challenges its facing. Discuss questions, including: - Telehealth's role in expanding access to mental healthcare is clear, but what about other conditions? - Was access expanded for all patients or do modern delivery methods leave some patients behind - How do telehealth costs compare to in-person costs? - What happens to the value proposition if unit cost savings is off the table?

Description: This will be the most fun you'll ever have learning about applying rigorous credibility standards in the real world! Measuring provider performance is crucial to value-based care, but no one wants to be told their data is not credible-so, what's an actuary to do? This session will mix in-depth theory with the messy realities of program implementation to give you tools for the real world. Whether or not you have ASOP 25 framed on your bedside table, you'll walk away from this session ready for the next time a business partner insists that 50 members 'is absolutely credible'.